Use of natriuretic peptide for treating heart failure

Details Use of natriuretic peptide for treating heart failure Use of natriuretic peptide for treating heart failure

2006-04-07

2010-06-08

Tate, Christopher R. (Department: 1654)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Peptide containing doai

Reexamination Certificate

active

07732406

ABSTRACT:
The present invention relates to the use of a natriurectic peptide, such as urodilatin, for treating a patient suffering from heart failure, such as acute decompensated heart failure. Preferably, a composition comprising an effective amount of urodilatin is intravenously administered to the patient continuously through a time period of at least 24 hours and up to 120 hours, preferably at least 48 hours.

REFERENCES:
patent: 4751284 (1988-06-01), Forssmann
patent: 4782044 (1988-11-01), Forssmann
patent: 4895932 (1990-01-01), Forssmann
patent: 5449751 (1995-09-01), Forssmann et al.
patent: 5461142 (1995-10-01), Forssmann et al.
patent: 5514670 (1996-05-01), Friedman et al.
patent: 5571789 (1996-11-01), Fluge et al.
patent: 5767239 (1998-06-01), Immer et al.
patent: 6831064 (2004-12-01), Forssmann et al.
patent: 2004/0203081 (2004-10-01), James et al.
Elsner et al., American Heart Journal, 1995, vol. 129, No. 4, pp. 766-773.
Levin et al., New England Journal of Medicine, 1998, vol. 339, No. 5, pp. 321-328.
Elsner et al., American Heart Journal, 1995, vol. 129, pp. 766-773.
Cleland, John, G.F., et al., “Clinical Trials Update from the European Society of Cardiology Meeting 2005: Care-HF Extension Study, Essential, CIBIS-III, S-ICD, Issue-2, Stride-2, Sofa, Imagine, Preami, Sirius-II and Active;”The European Journal of Heart Failure; 2005; vol. 7; pp. 1070-1075.
Elsner, Dietmar, MD, et al., “Efficacy of Prolonged Infusion of Urodilatin [ANP-(95-126)] in Patients with Congestive Heart Failure;”American Heart Journal; Apr. 1995; vol. 129; No. 4; pp. 766-773.
Kentsch, M., et al., “Haemodynamic and Renal Effects of Urodilatin Bolus Injections in Patients with Congestive Heart Failure;” Presented at the25th Annual Meeting of the European Society for Clinical Investigation; Apr. 3-6, 1991; Pisa, Italy; pp. 662-669.
Mitrovic, Veselin, MD, et al., “Effects of the Renal Natriuretic Peptide Urodilatin (Ularitide) in Patients with Decompensated Chronic Heart Failure: A Double-Blind, Placebo-Controlled, Ascending-Dose Trial;”American Heart Journal, Dec. 2005, vol. 150, No. 6, pp. 8 pages.
Kentsch et al., Haemodynamic and renal effects of urodilatin bolus injections in patients with congestive heart failure, Eur. J. Clin. Invest. 22(10): 662-69 (1992).
Kentsch et al., Severe hypotension and bradycardia after continuous intravenous infusion of urodilatin (ANP 95-126) in a patient with congestive heart failure, Eur. J. Clin. Invest. 25(4): 281-83 (1995).
Burger et al., Effect of nesiritide (B-type natriuretic peptide) and dobutamine on ventricular arrhythmias in the treatment of patients with acutely decompensated congestive heart failure: The Precedent study, Am. Heart J. 144: 1102-08 (2002).
Dorner et al., Hemodynamic effects of continuous urodilatin infusion: A dose-finding study, Clin. Pharmacol. Ther. 64(3): 322-30 (1998).
Sackner-Bernstein et al., Risk of Worsening Renal Function With Nesiritide in Patients With Acutely Decompensated Heart Failure, Circulation 111(112): 1487-91 (2005).
Ha et al., Dendroaspis natriuretic peptide protects the post-ischemic myocardial injury, Regul. Pept. 133: 13-19 (2006).
Oikawa et al., Cloning and sequence analysis of cDNA encoding a precursor for human atrial natriuretic poly peptide, Nature 309(5970): 724-26 (1984).
Nakayama et al., mRNA sequence for human cardiodilatin-atrial natriuretic factor precursor and regulation of precursor mRNA in rat atria, Nature 310(5979): 699-701 (1984).
Greenberg et al., Nucleotide sequence of the gene encoding human atrial natriuretic factor precursor, Nature 312 (5995): 656-58 (1984).
Seidman et al., Molecular studies of the atrial natriuretic factor gene, Hypertension 7(3 pt. 2): 131-34 (1985).
Hobbs et al., Hemodynamic Effects of a Single Intravenous Injection of Synthetic Human Brain Natriuretic Peptide in Patients With Heart Failure Secondary to Ischemic or Idiopathic Dilated Cardiomyopathy, Am. J. Cardiol. 78(8): 896-901 (1996).
Northridge et al., Atrial natriuretic factor in chronic heart failure, Herz 16(2): 92-101 (1991).
Schulz-Knappe et al., Isolation and structural analysis of “urodilatin”, a new peptide of the cardiodilatin-(ANP)-family, extracted from human urine, Klin. Wochenschr. 66(17): 752-59 (1988).
Forssmann et al., The renal urodilatin system: clinical implications, Cardiovasc. Res. 51(3): 450-62 (2001).
Abassi et al., Renal and systemic effects of urodilatin in rats with high-output heart failure, Am. J. Physiol. Renal Physiol. 262: 615-21 (1992).
Riegger et al., Effects of ANP-(95-126) in dogs before and after induction of heart failure, Am. J. Physiol. Heart Circ. Physiol. 259: H1643-48 (1990).
Saxenhofer et al., Urodilatin, a natriuretic factor from kidneys, can modify renal and cardiovascular function in men, Am. J. Physiol. Renal Physiol. 259: 832-38 (1990).
Bestle et al., Cardiovascular, endocrine, and renal effects of urodilatin in normal humans, Am. J. Physiol. Regulatory Integrative Comp. Physiol. 276: 684-95 (1999).
Munzel et al., Mechanisms involved in the response to prolonged infusion of atrial natriuretic factor in patients with chronic heart failure, Circulation 83(1): 191-201 (1991).
Takahashi et al., Cyclic GMP Production by ANP, BNP, and NO during Worsening and Improvement of Chronic Heart Failure, Jpn. Heart J. 44(5): 713-24 (2003).
Mills et al., Sustained hemodynamic effects of an infusion of nesiritide (human b-type natriuretic peptide) in heart failure: A randomized, double-blind, placebo-controlled clinical trial, J. Am. Coll. Cardiol. 34(1): 155-62 (1999).
Publication Committee for the VMAC Investigators, Intravenous Nesiritide vs Nitroglycerin for Treatment of Decompensated Congestive Heart Failure: A Randomized Controlled Trial, JAMA 287(12): 1531-40 (2002).
Cowie et al., Clinical applications of B-type natriuretic peptide (BNP) testing, Eur. Heart J. 24(19): 1710-18 (2003).
Francis, Acute decompensated heart failure: The cardiorenal syndrome, Clev. Clin. J. Med. 73(Supp. 2): S8-S13 (2006).
Wang et al., Nesiritide Does Not Improve Renal Function in Patients With Chronic Heart Failure and Worsening Serum Creatinine, Circulation 110: 1620-25 (2004).
Akhter et al., Effect of elevated admission serum creatinine and its worsening on outcome in hospitalized patients with decompensated heart failure, Am. J. Cardiol. 94(7): 957-60 (2004).
Gagelmann et al., Urodilatin (CDD/ANP-95-126) is not biologically inactivated by a peptidase from dog kidney cortex membranes in contrast to atrial natriuretic peptide/cardiodilatin (α-hANP/CDD-99-126), FEBS Lett. 233(2): 249-54 (1988).
Vesely, Natriuretic peptides and acute renal failure, Am. J. Physiol. Renal Physiol. 285: F167-F177 (2003).
Luss et al., Ularitide Improves Hemodynamics and Dyspnea in Patients with Decompensated Congestive Heart Failure without Deleterious Effect on Renal Function (Meeting Abstract), Circulation 112(17 Supp. II): 425 (2005).
Mitrovic et al., Ularitide Exerts Beneficial Hemodynamic Effects and Improves Symptoms in Patients with Decompensated Congestive Heart Failure (Meeting Abstract), Circulation 112(17 Supp. II): 453-54 (2005).
Mitrovic et al., Urodilatin induces cGMP-mediated haemodynamic effects in patients with decompensated congestive heart failure (Press Release), Deutsche Gesellschaft fur Kardiologie—Herz—und Kreislaufforschunt e.V. (DGK), 2004.
Mitrovic et al., Hemodynamic and neurohumoral effects of urodilatin in patients with decompensated congestive heart failure. Abstract from German Journal of Cardiology of 70th Annual Meeting of the German Society of Cardiology—Cardiac and Cardiovascular Research of Apr. 15-17, 2004, Mannheim. Z Kardiol 93 (suppl 3): III-423 V1580Z, 2004; Abstract V1580.
Mitrovic et al., Urodilatin induces cGMP-mediated haemodynamic effects in patients with decompensated congestive heart failure. Abstract from ESC Congress 2004. Eur. Heart Journal, 25 (Suppl):425; Abstract 2639, Aug. 2004.
Mitrovic et al., Haemodynamic and neurohumoral effects of the renal natriuretic peptide urodilatin in

Affiliated with

Also associated with

Rating

Use of natriuretic peptide for treating heart failure does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Use of natriuretic peptide for treating heart failure, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of natriuretic peptide for treating heart failure will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4178691